Related research by field

Related research

This bibliography consists of research that is not specifically about adverse effects of 5-alpha reductase inhibitors (5-ARIs), but could inform explanation, diagnosis or treatment of lasting dysfunctions after use of 5-ARIs. See also: Special topics

Cancer
Dermatology
Endocrinology, andrology & sexual medicine
Epidemiology & pharmacovigilance
Genetics
Geriatrics
Neuroendocrinology
Ophthalmology
Periodontology
Pharmacology & biochemistry
Psychiatry & neurology
Sports medicine
Urology & prostate cancer

Cancer

↑ back to top

Dermatology

↑ back to top

Babbush KM, Andriano TM, Cohen SR. Anti-androgen therapy in hidradenitis suppurativa: finasteride for females. Clin Exp Dermatol. 2021 Jul 14. doi:10.1111/ced.14847 • PubMed

Camacho FM, García-Hernández MJ, Fernández-Crehuet JL. Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old. Br J Dermatol. 2008 May. doi:10.1111/j.1365-2133.2008.08509.x • PubMed

Hatanaka T, Lulic Z, Mefo T, Booth C, Harrison E, Ong G. Change in hair growth-related gene expression profile in human isolated hair follicles induced by 5-alpha reductase inhibitors – dutasteride and finasteride – in the presence of testosterone. Singapore Med J. 2022 Sep. doi:10.11622/smedj.2021080 • Full text via journal • PubMed

Karagaiah P, Daveluy S, Ortega-Loayza A, et al. Update on hormonal therapy in hidradenitis suppurativa. J Drugs Dermatol. 2023. doi:10.36849/JDD.6235 • PubMed

Keene S, Goren A. Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatol Ther. 2011. doi:10.1111/j.1529-8019.2011.01407.x • PubMed

Moghetti P, Castello R, Magnani CM, et al. Clinical and hormonal effects of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism. J Clin Endocrinol Metab. 1994. doi:10.1210/jcem.79.4.7962284 • PubMed

Motofei IG, Rowland DL, Baconi DL, et al. Androgenetic alopecia; drug safety and therapeutic strategies. Expert Opin Drug Saf. 2018. doi:10.1080/14740338.2018.1430765 • PubMed

[Comment] Ong G, Manyak M, Lulic Z. Letter to the editor: Androgenetic alopecia; drug safety and therapeutic strategies. Expert Opin Drug Saf. 2018 Jun. doi:10.1080/14740338.2018.1470744 • PubMed

[Comment] Motofei IG, Rowland DL. Response to the letter to the editor; Androgenetic alopecia; drug safety and therapeutic strategies. Expert Opin Drug Saf. 2018 Jun. doi:10.1080/14740338.2018.1470749 • PubMed

Nguyen QH, Chen T, Wang X, Chen Y, Chien P. Finasteride inhibits 5 alpha-reductase activity in human dermal fibroblasts: prediction of its therapeutic application in androgen-related skin diseases. Int J Dermatol. 1995 Oct. doi:10.1111/j.1365-4362.1995.tb04663.x • PubMed

Sawaya ME, Blume-Peytavi U, Mullins DL, et al. Effects of finasteride on apoptosis and regulation of the human hair cycle. J Cutan Med Surg. 2002 Jan-Feb. doi:10.1007/s10227-001-0024-y • PubMed

Seo JO, Yumnam S, Jeong KW, Kim SY. Finasteride inhibits melanogenesis through regulation of the adenylate cyclase in melanocytes and melanoma cells. Arch Pharm Res. 2018 Mar. doi:10.1007/s12272-018-1002-x • PubMed • PMC full text

[⚠️ Funded by an “educational grant” from Merck] Stough D, Stenn K, Haber R, et al. Psychological effect, pathophysiology, and management of androgenetic alopecia in men. Mayo Clin Proc. 2005. doi:10.4065/80.10.1316 • PubMed

Wakisaka N, Taira Y, Ishikawa M, et al. Effectiveness of finasteride on patients with male pattern baldness who have different androgen receptor gene polymorphism. J Investig Dermatol Symp Proc. 2005 Dec. doi:10.1111/j.0022-202X.2005.10123.x • PubMed

Yamazaki M, Sato A, Toyoshima KE, et al. Polymorphic CAG repeat numbers in the androgen receptor gene of female pattern hair loss patients. J Dermatol. 2011 Jul. doi:10.1111/j.1346-8138.2010.01060.x • PubMed

Endocrinology, andrology and sexual medicine

↑ back to top

Anawalt BD. Is dihydrotestosterone a classic hormone? Endocr Rev. 2017 Jun 1. doi:10.1210/er.2017-00091 • PubMed

Baker RC, Bergeson RL, Yi YA, Ward EE, Morey AF. Dutasteride in the long-term management of stuttering priapism. Transl Androl Urol. 2020 Feb. doi:10.21037/tau.2019.07.15 • PubMed • PMC full text

Bissegger S, Langlois VS. Androgens modulate gene expression and specific DNA methylation pattern of steroid 5α-reductases in the frog Silurana tropicalis. Gen Comp Endocrinol. 2016. doi:10.1016/j.ygcen.2016.03.021 • PubMed

Boehmer AL, Brinkmann AO, Nijman RM, et al. Phenotypic variation in a family with partial androgen insensitivity syndrome explained by differences in 5alpha dihydrotestosterone availability. J Clin Endocrinol Metab. 2001. doi:10.1210/jcem.86.3.7333 • PubMed

Borst SE, Yarrow JF, Conover CF, et al. Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial. Am J Physiol Endocrinol Metab. 2014 Feb 15. doi:10.1152/ajpendo.00592.2013 • PubMed • PMC full text

Borst SE, Yarrow JF, Fernandez C, et al. Cognitive effects of testosterone and finasteride administration in older hypogonadal men. Clin Interv Aging. 2014 Aug 12. doi:10.2147/CIA.S61760 • PubMed • PMC full text

Chávez B, Ramos L, García-Becerra R, Vilchis F. Hamster SRD5A3 lacks steroid 5α-reductase activity in vitro. Steroids. 2015;94:41–50. doi:10.1016/j.steroids.2014.11.005 • PubMed

Huh JS, Chung BH, Hong CH, et al. The effects of testosterone replacement on penile structure and erectile function after long-term castration in adult male rats. Int J Impot Res. 2018. doi:10.1038/s41443-017-0010-6 • PubMed

Karakas SE, Surampudi P. New biomarkers to evaluate hyperandrogenemic women and hypogonadal men. Adv Clin Chem. 2018. doi:10.1016/bs.acc.2018.06.001 • PubMed

Lugg JA, Rajfer J, González-Cadavid NF. Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. Endocrinology. 1995 Apr;136(4):1495-501. doi:10.1210/endo.136.4.7534702 • PubMed

Rachid-Filho D, Cavalcanti AG, Favorito LA, Costa WS, Sampaio FJ. Treatment of recurrent priapism in sickle cell anemia with finasteride: a new approach. Urology. 2009 Nov. doi:10.1016/j.urology.2009.04.071 • PubMed

Sansone A, Kliesch S, Dugas M, et al. Serum concentrations of dihydrotestosterone are associated with symptoms of hypogonadism in biochemically eugonadal men. J Endocrinol Invest. 2021. doi:10.1007/s40618-021-01561-0 • PubMed • PMC full text

Sasaki G, Ishii T, Hori N, Amano N, Homma K, Sato S, Hasegawa T. Effects of pre- and post-pubertal dihydrotestosterone treatment on penile length in 5α-reductase type 2 deficiency. Endocr J. 2019 Sep 28. doi:10.1507/endocrj.EJ19-0111 • Pu bMed

Schulster M, Bernie AM, Ramasamy R. The role of estradiol in male reproductive function. Asian J Androl. 2016 May-Jun. doi:10.4103/1008-682X.173932 • PubMed • PMC full text

Swerdloff RS, Dudley RE, Page ST, Wang C, Salameh WA. Dihydrotestosterone: biochemistry, physiology, and clinical implications of elevated blood levels. Endocr Rev. 2017 Jun 1. doi:10.1210/er.2016-1067 • PubMed • PMC full text

Tut TG, Ghadessy FJ, Trifiro MA, Pinsky L, Yong EL. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J Clin Endocrinol Metab. 1997 Nov. doi:10.1210/jcem.82.11.4385 • PubMed

Yamana K, Labrie F, Luu-The V. Human type 3 5α-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride. Horm Mol Biol Clin Investig. 2010 Aug 1. doi:10.1515/HMBCI.2010.035 • PubMed

[⚠️ All authors have a relationship to telehealth company Keeps, as Medical Director, employee of parent company or medical advisor] Young PC, Mahajan C, Shapiro J, Tosti A. Digital health platforms expand access and improve care for male androgenetic alopecia. Int J Dermatol. 2023. doi:10.1111/ijd.16452 • PubMed

Epidemiology & pharmacovigilance

↑ back to top

Souverein PC, Herings RM, De la Rosette JJ, Man in ‘t Veld AJ, Farmer RD, Leufkens HG. Evaluating adverse cardiovascular effects of drug treatment for benign prostatic hyperplasia (BPH): methodological considerations. J Clin Epidemiol. 2001. doi:10.1016/s0895-4356(00)00327-9 • PubMed

Genetics

↑ back to top

Buccitelli C, Selbach M. mRNAs, proteins and the emerging principles of gene expression control. Nat Rev Genet. 2020 Oct. doi:10.1038/s41576-020-0258-4 • PubMed

da Cruz GK, Martins MIM, Antunes FTT, et al. Evaluation of the efficacy and toxicity of oral and topical pumpkin oil on the hair growth of mice. Acta Histochem. 2022 Apr 18. doi:10.1016/j.acthis.2022.151894 • PubMed. [DNA damage in minoxidil treatment group]

Ellis JA, Stebbing M, Harrap SB. Polymorphism of the androgen receptor gene is associated with male pattern baldness. J Invest Dermatol. 2001 Mar. doi:10.1046/j.1523-1747.2001.01261.x • PubMed

Grigorova M, Punab M, Kahre T, et al. The number of CAG and GGN triplet repeats in the Androgen Receptor gene exert combinatorial effect on hormonal and sperm parameters in young men. Andrology. 2017 May. doi:10.1111/andr.12344 • PubMed

Katharopoulos E, Sauter K, Pandey AV, Flück CE. In silico and functional studies reveal novel loss-of-function variants of SRD5A2, but no variants explaining excess 5α-reductase activity. J Steroid Biochem Mol Biol. 2019 Jun. doi:10.1016/j.jsbmb.2019.01.017 • Pu bMed

Levy-Nissenbaum E, Bar-Natan M, Frydman M, Pras E. Confirmation of the association between male pattern baldness and the androgen receptor gene. Eur J Dermatol. 2005 Sep-Oct. PubMed

Lin ZM, Fan DD, Jin S, Liu ZL, Niu YN. Methylated CpG dinucleotides in the 5-α reductase 2 gene may explain finasteride resistance in benign prostatic enlargement patients. Asian J Androl. 2020 Nov 20. doi:10.4103/aja.aja_63_20 • PubMed

Lolli F, Pallotti F, Rossi A, Fortuna MC, Caro G, Lenzi A, Sansone A, Lombardo F. Androgenetic alopecia: a review. Endocrine. 2017 Jul. doi:10.1007/s12020-017-1280-y • PubMed

Medline Plus: SRD5A2 gene.

Samtani R, Bajpai M, Ghosh PK, Saraswathy KN. A49T, R227Q and TA repeat polymorphism of steroid 5 alpha-reductase type II gene and Hypospadias risk in North Indian children. Meta Gene. 2014 Dec 11. doi:10.1016/j.mgene.2014.11.003 • PubMed

Stiles AR, Russell DW. SRD5A3: A surprising role in glycosylation. Cell. 2010 Jul 23. doi:10.1016/j.cell.2010.07.003 • 20655462 • PMC full text

Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest. 1993 Aug;92(2):903-10. doi:10.1172/JCI116665 • PubMed • PMC full text

Tirabassi G, Cignarelli A, Perrini S, et al. Influence of CAG repeat polymorphism on the targets of testosterone action. Int J Endocrinol. 2015. doi:10.1155/2015/298107 • PubMed • Full text

Zimmermann N, Zschocke J, Perisic T, Yu S, Holsboer F, Rein T. Antidepressants inhibit DNA methyltransferase 1 through reducing G9a levels. Biochem J. 2012. doi:10.1042/BJ20120674 • PubMed

Geriatrics

↑ back to top

Na HR, Cho ST, Lee JS, Kim S. P4‐324: Finasteride treatment of hypersexuality associated with vascular dementia and underlying benign prostate hyperplasia. Alzheimer’s & Dementia. 2008;4(4S Part 24):T767. doi:10.1016/j.jalz.2008.05.2394

Na HR, Lee JW, Park SM, Ko SB, Kim S, Cho ST. Inappropriate sexual behaviors in patients with vascular dementia: possible response to finasteride. J Am Geriatr Soc. 2009 Nov. doi:10.1111/j.1532-5415.2009.02536.x • PubMed

Neuroendocrinology

↑ back to top

Agis-Balboa RC, Guidotti A, Pinna G. 5α-reductase type I expression is downregulated in the prefrontal cortex/Brodmann’s area 9 (BA9) of depressed patients. Psychopharmacology (Berl). 2014 Sep. doi:10.1007/s00213-014-3567-5 • PubMed • PMC full text

Bali A, Jaggi AS. Multifunctional aspects of allopregnanolone in stress and related disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3. doi:10.1016/j.pnpbp.2013.09.005 • PubMed

Bortolato M, Devoto P, Roncada P, et al. Isolation rearing-induced reduction of brain 5α-reductase expression: relevance to dopaminergic impairments. Neuropharmacology. 2011 Jun. doi:10.1016/j.neuropharm.2011.01.013 • PubMed

Chen S, Gao L, Li X, Ye Y. Allopregnanolone in mood disorders: mechanism and therapeutic development. Pharmacol Res. 2021 May 18. doi:10.1016/j.phrs.2021.105682 • PubMed

Christian CA. Nucleus-specific modulation of phasic and tonic inhibition by endogenous neurosteroidogenesis in the murine thalamus. Synapse. 2020 May. doi:10.1002/syn.22144 • PubMed • PMC full text

Duong P, Tenkorang MAA, Trieu J, McCuiston C, Rybalchenko N, Cunningham RL. Neuroprotective and neurotoxic outcomes of androgens and estrogens in an oxidative stress environment. Biol Sex Differ. 2020 Mar 29. doi:10.1186/s13293-020-0283-1 • PubMed • PMC full text

Frau R, Bini V, Pes R, et al. Inhibition of 17α-hydroxylase/C17,20 lyase reduces gating deficits consequent to dopaminergic activation. Psychoneuroendocrinology. 2014 Jan. doi:10.1016/j.psyneuen.2013.09.014 • PubMed • PMC full text

Frau R, Mosher LJ, Bini V, et al. The neurosteroidogenic enzyme 5α-reductase modulates the role of D1 dopamine receptors in rat sensorimotor gating. Psychoneuroendocrinology. 2016. doi:10.1016/j.psyneuen.2015.09.014 • PubMed

Giatti S, Diviccaro S, Falvo E, Miguel Garcia-Segura L, Melcangi RC. Physiopathological role of the enzymatic complex 5α-reductase and 3α/β-hydroxysteroid oxidoreductase in the generation of progesterone and testosterone neuroactive metabolites. Front Neuroendocrinol. 2020. doi:10.1016/j.yfrne.2020.100836 • PubMed

Giatti S, Diviccaro S, Serafini MM, et al. Sex differences in steroid levels and steroidogenesis in the nervous system: Physiopathological role. Front Neuroendocrinol. 2020. doi:10.1016/j.yfrne.2019.100804 • PubMed

Giatti S, Garcia-Segura LM, Barreto GE, Melcangi RC. Neuroactive steroids, neurosteroidogenesis and sex. Prog Neurobiol. 2019. doi:10.1016/j.pneurobio.2018.06.007 • PubMed

Hill RA, Pompolo S, Jones ME, Simpson ER, Boon WC. Estrogen deficiency leads to apoptosis in dopaminergic neurons in the medial preoptic area and arcuate nucleus of male mice. Mol Cell Neurosci. 2004 Dec. doi:10.1016/j.mcn.2004.04.012 • PubMed

Kalakh S, Mouihate A. Enhanced remyelination during late pregnancy: involvement of the GABAergic system. Sci Rep. 2019 May 22. doi:10.1038/s41598-019-44050-4 • PubMed • PMC full text

Marciniak E, Młotkowska P, Roszkowicz-Ostrowska K, Ciska E, Misztal T. Involvement of neurosteroids in the control of prolactin secretion in sheep under basal, stressful and pregnancy conditions. Theriogenology. 2022. doi:10.1016/j.theriogenology.2022.08.013 • PubMed

Melcangi RC, Panzica GC. Allopregnanolone: state of the art. Prog Neurobiol. 2014 Feb. doi:10.1016/j.pneurobio.2013.09.005 • PubMed

Melcangi RC, Riva MA, Fumagalli F, Magnaghi V, Racagni G, Martini L. Effect of progesterone, testosterone and their 5 alpha-reduced metabolites on GFAP gene expression in type 1 astrocytes. Brain Res. 1996. doi:10.1016/0006-8993(95)01302-4 • PubMed

Meng Z, Rowlett JK. Self-administration of progesterone and synthetic neuroactive steroids by male rhesus monkeys. Drug Alcohol Depend. 2016 Aug 1. doi:10.1016/j.drugalcdep.2016.05.029 • PubMed • PMC full text

Misztal T, Młotkowska P, Marciniak E, Roszkowicz-Ostrowska K, Misztal A. Involvement of neurosteroids in the control of hypothalamic-pituitary-adrenal axis activity in pregnant sheep under basal and stressful conditions. Theriogenology. 2021 Aug 20. doi:10.1016/j.theriogenology.2021.08.026 • PubMed

Nasiri M, Nikolaou N, Parajes S, et al. 5α-reductase type 2 regulates glucocorticoid action and metabolic phenotype in human hepatocytes. Endocrinology. 2015 Aug. doi:10.1210/en.2015-1149 • PubMed • PMC full text

Pinacho-Garcia LM, Valdez RA, Navarrete A, Cabeza M, Segovia J, Romano MC. The effect of finasteride and dutasteride on the synthesis of neurosteroids by glioblastoma cells. Steroids. 2020 Mar. doi:10.1016/j.steroids.2019.108556 • PubMed

Pinna G. Allopregnanolone, the neuromodulator turned therapeutic agent: Thank you, next? Front Endocrinol (Lausanne). 2020 May 14. doi:10.3389/fendo.2020.00236 • PubMed • PMC full text

Samba Reddy D, Ramanathan G. Finasteride inhibits the disease-modifying activity of progesterone in the hippocampus kindling model of epileptogenesis. Epilepsy Behav. 2012 Sep. doi:10.1016/j.yebeh.2012.05.024 • PubMed

Scarduzio M, Panichi R, Pettorossi VE, Grassi S. Synaptic long-term potentiation and depression in the rat medial vestibular nuclei depend on neural activation of estrogenic and androgenic signals. PLoS One. 2013 Nov 12. doi:10.1371/journal.pone.0080792 • PubMed • PMC full text

Shen ZJ, Lu YL, Chen ZD, Chen F, Chen Z. Effects of androgen and ageing on gene expression of vasoactive intestinal polypeptide in rat corpus cavernosum. BJU Int. 2000 Jul. doi:10.1046/j.1464-410x.2000.00721.x • PubMed

Sun YH, Gao X, Tang YJ, Xu CL, Wang LH. Androgens induce increases in intracellular calcium via a G protein-coupled receptor in LNCaP prostate cancer cells. J Androl. 2006 Sep-Oct. doi:10.2164/jandrol.106.000554 • PubMed

Tesone AJ, Regueira E, Canosa LF, Ceballos NR. 5α-Reductase, an enzyme regulating glucocorticoid action in the testis of Rhinella arenarum (Amphibia: Anura). Gen Comp Endocrinol. 2012 May 1. doi:10.1016/j.ygcen.2012.01.004 • PubMed

Tokuda K, Izumi Y, Zorumski CF. Ethanol enhances neurosteroidogenesis in hippocampal pyramidal neurons by paradoxical NMDA receptor activation. J Neurosci. 2011 Jul 6. doi:10.1523/JNEUROSCI.1660-11.2011 • PubMed • PMC full text

van Luijtelaar G, Budziszewska B, Tetich M, Lasoń W. Finasteride inhibits the progesterone-induced spike-wave discharges in a genetic model of absence epilepsy. Pharmacol Biochem Behav. 2003 Jul. doi:10.1016/s0091-3057(03)00162-x • PubMed

Ophthalmology

↑ back to top

Fusi-Rubiano W, Saedon H, Patel V, Yang YC. Oral medications for central serous chorioretinopathy: a literature review. Eye (Lond). 2020 May. DOI • PubMed • PMC full text

Gülkaş S, Şahin Ö. Current therapeutic approaches to chronic central serous chorioretinopathy. Turk J Ophthalmol. 2019 Feb 28. DOI • PubMed • PMC full text

Moisseiev E, Holmes AJ, Moshiri A, Morse LS. Finasteride is effective for the treatment of central serous chorioretinopathy. Eye (Lond). 2016 Jun. DOI • PubMed • PMC full text

Rocha EM, Wickham LA, da Silveira LA, et al. Identification of androgen receptor protein and 5alpha-reductase mRNA in human ocular tissues. Br J Ophthalmol. 2000. doi:10.1136/bjo.84.1.76 • PubMed • PMC full text

Periodontology

↑ back to top

Kasasa SC, Soory M. The combined effects of TGF-beta, IGF and PDGF on 5alpha-reductase activity on androgen substrates in human gingival tissue. Inflammopharmacology. 1998. doi:10.1007/s10787-998-0021-5 • PubMed

Southren AL, Rappaport SC, Gordon GG, Vittek J. Specific 5 alpha-dihydrotestosterone receptors in human gingiva. J Clin Endocrinol Metab. 1978. doi:10.1210/jcem-47-6-1378 • PubMed

Pharmacology & biochemistry

↑ back to top

Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M. An overview on 5alpha-reductase inhibitors. Steroids. 2010. doi:10.1016/j.steroids.2009.10.005 • PubMed

Bortolato M, Frau R, Orrù M, et al. Antipsychotic-like properties of 5-alpha-reductase inhibitors. Neuropsychopharmacology. 2008 Dec. doi:10.1038/npp.2008.39 • PubMed

Bosse GD, Cadeddu R, Floris G, et al. The 5α-reductase inhibitor finasteride reduces opioid self-administration in animal models of opioid use disorder. J Clin Invest. 2021 Apr 13. doi:10.1172/JCI143990 • PubMed

Bull HG, Garcia-Calvo M, Andersson S, et al. Mechanism-based inhibition of human steroid 5α-reductase by finasteride: enzyme-catalyzed formation of NADP−dihydrofinasteride, a potent bisubstrate analog inhibitor. Journal of the American Chemical Society. 1996. doi:10.1021/ja953069t

Chávez B, Ramos L, García-Becerra R, Vilchis F. Hamster SRD5A3 lacks steroid 5α-reductase activity in vitro. Steroids. 2015;94:41–50. doi:10.1016/j.steroids.2014.11.005 • PubMed

Devoto P, Frau R, Bini V, et al. Inhibition of 5α-reductase in the nucleus accumbens counters sensorimotor gating deficits induced by dopaminergic activation. Psychoneuroendocrinology. 2012 Oct. doi:10.1016/j.psyneuen.2011.09.018 • PubMed • PMC full text

Eckstein M, Rea M, Fondufe-Mittendorf YN. Transient and permanent changes in DNA methylation patterns in inorganic arsenic-mediated epithelial-to-mesenchymal transition. Toxicol Appl Pharmacol. 2017 Sep 15. doi:10.1016/j.taap.2017.03.017 • PubMed • PMC full text

Ellsworth KP, Azzolina BA, Cimis G, Bull HG, Harris GS. Cloning, expression and characterization of rhesus macaque types 1 and 2 5alpha-reductase: evidence for mechanism-based inhibition by finasteride. J Steroid Biochem Mol Biol. 1998 Sep. doi:10.1016/s0960-0760(98)00059-4 • PubMed

Finn DA, Long SL, Tanchuck MA, Crabbe JC. Interaction of chronic ethanol exposure and finasteride: sex and strain differences. Pharmacol Biochem Behav. 2004 Jul. doi:10.1016/j.pbb.2004.04.016 • PubMed

Floris G, Scheggi S, Pes R, Bortolato M. The steroidogenic inhibitor finasteride reverses pramipexole-induced alterations in probability discounting. Brain Res Bull. 2022 Apr. doi:10.1016/j.brainresbull.2022.01.020 • PubMed

Fouad Mansour M, Pelletier M, Tchernof A. Characterization of 5α-reductase activity and isoenzymes in human abdominal adipose tissues. J Steroid Biochem Mol Biol. 2016 Jul. doi:10.1016/j.jsbmb.2016.02.003 • PubMed

Frau R, Pillolla G, Bini V, Tambaro S, Devoto P, Bortolato M. Inhibition of 5α-reductase attenuates behavioral effects of D1-, but not D2-like receptor agonists in C57BL/6 mice. Psychoneuroendocrinology. 2013 Apr. doi:10.1016/j.psyneuen.2012.07.014 • PubMed

Gorin-Meyer RE, Wiren KM, Tanchuck MA, Long SL, Yoneyama N, Finn DA. Sex differences in the effect of finasteride on acute ethanol withdrawal severity in C57BL/6J and DBA/2J mice. Neuroscience. 2007. doi:10.1016/j.neuroscience.2007.02.051 • PubMed • PMC full text

Han Y, Zhuang Q, Sun B, et al. Crystal structure of steroid reductase SRD5A reveals conserved steroid reduction mechanism. Nat Commun. 2021 Jan 19. doi:10.1038/s41467-020-20675-2 • PubMed

Ishii Y, Mukoyama H, Hata S. Metabolism of finasteride in rat hepatic microsomes: age and sex differences and effects of P450 inducers. Xenobiotica. 1994 Sep. doi:10.3109/00498259409043285 • PubMed

Khantham C, Yooin W, Sringarm K, et al. Effects on steroid 5-alpha reductase gene expression of Thai rice bran extracts and molecular dynamics study on SRD5A2. Biology (Basel). 2021 Apr 11. doi:10.3390/biology10040319 • PubMed

Kim D, Cho H, Eggers R, Kim SK, Ryu CS, Kim YJ. Development of a liquid chromatography/mass spectrometry-based inhibition assay for the screening of steroid 5-α reductase in human and fish cell lines. Molecules. 2021 Feb 8. doi:10.3390/molecules26040893 • PubMed

Kim HJ, Kim TJ, Kim YG, Seong C, Cho JH, Kim W, Lee KH, Kim DY. Antioxidant and antiproliferative activity of finasteride against glioblastoma cells. Pharmaceutics. 2021 Sep 6. doi:10.3390/pharmaceutics13091410 • PubMed

Koukoulis GN, Filiponi M, Gougoura S, Befani C, Liakos P, Bargiota Α. Testosterone and dihydrotestosterone modulate the redox homeostasis of endothelium. Cell Biol Int. 2022 Apr. doi:10.1002/cbin.11768 • PubMed

Kudryashov NV, Ivanova EA, Kalinina TS, et al. Antiexudative effects of finasteride and a new pyrazolo[c]pyridine derivative GIZh-72 in acetic acid-induced experimental peritonitis. Bull Exp Biol Med. 2020 Feb. doi:10.1007/s10517-020-04730-y • PubMed

Olayinka ET, Adewole KE. Ameliorative effect of morin on dutasteride-tamsulosin-induced testicular oxidative stress in rat. J Complement Integr Med. 2020 Dec 23. doi:10.1515/jcim-2019-0160 • PubMed

Paba S, Frau R, Godar SC, Devoto P, Marrosu F, Bortolato M. Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders. Curr Pharm Des. 2011. doi:10.2174/138161211795049589 • PubMed

Peng HM, Valentín-Goyco J, Im SC, et al. Expression in Escherichia coli, purification, and functional reconstitution of human steroid 5α-reductases. Endocrinology. 2020 Aug 1. doi:10.1210/endocr/bqaa117 • PubMed

Poirier AA, Côté M, Jarras H, et al. Peripheral neuroprotective and immunomodulatory effects of 5α-reductase inhibitors in Parkinson’s disease models. Front Pharmacol. 2022 Jul 22. doi:10.3389/fphar.2022.898067 • PubMed • PMC full text

[Preprint] Simmering JE, Welsh MJ, Schultz J, Narayanan NS. Use of glycolysis enhancing drugs has less risk of Parkinson’s disease than 5α-reductase inhibitors. medRxiv. Published online January 1, 2022. doi:10.1101/2022.04.01.22273312

Stamatiadis D, Bulteau-Portois MC, Mowszowicz I. Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol. 1988. doi:10.1111/j.1365-2133.1988.tb03474.x • PubMed

Wolf R, Schönfelder G, Paul M, Blume-Peytavi U. Nitric oxide in the human hair follicle: constitutive and dihydrotestosterone-induced nitric oxide synthase expression and NO production in dermal papilla cells. J Mol Med (Berl). 2003. doi:10.1007/s00109-002-0402-y • PubMed

Psychiatry & neurology

↑ back to top

Bortolato M, Cannas A, Solla P, Bini V, Puligheddu M, Marrosu F. Finasteride attenuates pathological gambling in patients with Parkinson disease. J Clin Psychopharmacol. 2012 Jun. doi:10.1097/JCP.0b013e3182549c2a • PubMed

Bortolato M, Muroni A, Marrosu F. Treatment of Tourette’s syndrome with finasteride. Am J Psychiatry. 2007 Dec. doi:10.1176/appi.ajp.2007.07060978 • PubMed

Koethe D, Bortolato M, Piomelli D, Leweke FM. Improvement of general symptoms in a chronic psychotic patient treated with finasteride: case report. Pharmacopsychiatry. 2008 May. doi:10.1055/s-2008-1058110 • PubMed. Erratum in: Pharmacopsychiatry. 2011 Jun;44(4):163.

Sports medicine

↑ back to top

Iannella L, Colamonici C, Curcio D, et al. 5α-reductase inhibitors: evaluation of their potential confounding effect on GC-C-IRMS doping analysis. Drug Test Anal. 2021 Jul 27. doi:10.1002/dta.3134 • PubMed

Urology & prostate cancer

↑ back to top

Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol. 2002 Apr. doi:10.1007/s00345-002-0248-5 • PubMed

Chu Y, Zhang M, Cui Y, et al. The effect of 5-α reductase inhibitor on Th1, Th2, and Th17 cell-related inflammatory response in BPH. World J Urol. 2023. doi:10.1007/s00345-023-04357-4 • PubMed

Ge R, Wang Z, Bechis SK, et al. DNA methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostate. Am J Pathol. 2015;185(3):870–882. doi:10.1016/j.ajpath.2014.11.020 • PubMed

Golbano JM, Lóppez-Aparicio P, Recio MN, Pérez-Albarsanz MA. Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line. Int J Oncol. 2008 Apr. doi:10.3892/ijo.32.4.919 • PubMed

Häggström S, Tørring N, Møller K, et al. Effects of finasteride on vascular endothelial growth factor. Scand J Urol Nephrol. 2002. doi:10.1080/003655902320131848 • PubMed

Jin R, Forbes C, Miller NL, et al. Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients. Prostate. 2022. doi:10.1002/pros.24410 • PubMed

Kuhlmann PK, Fischer SC, Howard LE, et al. Dutasteride improves nocturia but does not lead to better sleep: results from the REDUCE clinical trial. J Urol. 2021 Jun. doi:10.1097/JU.0000000000001640 • PubMed

Luo LM, Yang RD, Wang JM, et al. Association between 5α-reductase inhibitors therapy and incidence, cancer-specific mortality, and progression of prostate cancer: evidence from a meta-analysis. Asian J Androl. 2020 Sep-Oct. doi:10.4103/aja.aja_112_19 • PubMed • PMC full text

Marks LS. 5alpha-reductase: history and clinical importance. Rev Urol. 2004. PubMed • PMC full text

Mizoguchi S, Mori K, Shin T, Wang Z, DeFranco DB, Yoshimura N, Mimata H. Effects of dutasteride in a rat model of chemically induced prostatic inflammation-Potential role of estrogen receptor β. Prostate. 2020 Dec. doi:10.1002/pros.24071 • PubMed

Nguyen DD, Trinh QD, Bhojani N. Combination of tadalafil and finasteride for the treatment of urinary tract symptoms related to benign prostatic hyperplasia: commercialization of the prescribing cascade. Eur Urol. 2022. doi:10.1016/j.eururo.2022.01.009 • PubMed

Vaselkiv JB, Ceraolo C, Wilson KM, et al. 5-alpha reductase inhibitors and prostate cancer mortality among men with regular access to screening and health care. Cancer Epidemiol Biomarkers Prev. 2022 Jul 1. doi:10.1158/1055-9965.EPI-21-1234 • PubMed

[Editorial] Hamilton RJ. 5-alpha reductase inhibitor use and prostate cancer prevention: a victim of the times? Cancer Epidemiol Biomarkers Prev. 2022 Jul 1. doi:10.1158/1055-9965.EPI-22-0338 • PubMed

Zhang B, Chen X, Liu YH, et al. Periprostatic fat thickness measured on MRI correlates with lower urinary tract symptoms, erectile function, and benign prostatic hyperplasia progression. Asian J Androl. 2021 Jan-Feb. doi:10.4103/aja.aja_51_20 • PubMed • PMC full text

Zhang XH, Hu LQ, Zheng XM, Li SW. Apoptosis in rat erectile tissue induced by castration. Asian J Androl. 1999 Dec. PubMed • Journal full text

Zhu D, Srivastava A, Agalliu I, et al. Finasteride use and risk of bladder cancer in a multiethnic population. J Urol. 2021 Jul. doi:10.1097/JU.0000000000001694 • PubMed